abbvie inc schizophrenia drug news - Search News

AbbVie, schizophrenia

MarketWatch on MSN · 2d

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Stocktwits on MSN · 3d

AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug trial failed to meet their primary endpoint. AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily,

Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

Despite setback, AbbVie’s big bet on neuroscience has yet to play out

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

BioPharma Dive3d

AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results